FilingSEC EDGAR8-K
Veru to Advance Sabizabulin into Phase 2 Clinical Trial for Pancreatic Cancer
· SEC accepted
StagePhase 2
Filing content
Veru announced it will advance sabizabulin into a Phase 2 clinical trial for pancreatic cancer. The company will discontinue its research on sabizabulin for cardiovascular disease to focus on this new oncology indication.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…